This week, Lund-based Abliva announced the completion of the phase Ia/Ib study with the company's lead candidate KL1333. The study was designed to evaluate the safety and pharmacokinetics for KL1333, which is an important step before the upcoming phase II/III efficacy study that is expected to begin later this year. BioStock has spoken with Abliva's chief medical officer Magnus Hansson to find out more.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se